VICTOR VASQUEZ: Open Payments
NPI 1972217446 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,111 in 40 payments from 16 companies in 2025. Trend: 2023 $93 · 2024 $1,063 · 2025 $1,111
Food & beverage: $1,111
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $327 |
| Novo Nordisk Inc | 5 | $137 |
| Exact Sciences Corporation | 5 | $116 |
| AstraZeneca Pharmaceuticals LP | 4 | $81 |
| Lilly USA, LLC | 3 | $66 |
| Actelion Pharmaceuticals US, Inc. | 2 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $49 |
| PFIZER INC. | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $42 |
| GlaxoSmithKline, LLC. | 2 | $35 |
Products named: REPATHA, The Cologuard Plus Collection Kit, AIRSUPRA, OPSUMIT, Rybelsus, XIFAXAN, OTEZLA, MOUNJARO.
Industry payments across CT — which companies pay providers there.
